Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Matthew D HellmannBarzin Y NabetHira RizviAadel A ChaudhuriDaniel K WellsMark P S DunphyJacob J ChabonChih Long LiuAngela B HuiKathryn C ArbourJia LuoIsabel R PreeshagulEverett J ModingDiego AlmanzaRene F BonillaJennifer L SauterHyejin ChoiMegan TenetMohsen Abu-AkeelAndrew J PlodkowskiRocio Perez JohnstonChristopher H YooRyan B KoHenning StehrLinda GojenolaHeather A WakeleeSukhmani K PaddaJoel W NealJamie E ChaftMark G KrisCharles M RudinTaha MerghoubBob T LiAsh A AlizadehMaximilian DiehnPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
ctDNA analysis can noninvasively identify minimal residual disease in patients with long-term responses to PD-(L)1 blockade and predict the risk of eventual progression. If validated, ctDNA surveillance may facilitate personalization of the duration of immune checkpoint blockade and enable early intervention in patients at high risk for progression.